Chinanews Shandong News, February 23 (Sha Jianlong) Shandong Henglu Biotechnology Co., Ltd. (hereinafter referred to as Shandong Henglu Biotechnology) signed a capital support agreement with Huayao Capital on the 22nd. On the basis of investing 30 million yuan (RMB, the same below) in 2020, Huayao Capital officially followed up with 24 million yuan on the same day to support Shandong Henglu Biological in promoting the development of leading projects such as human milk oligosaccharides and high-purity rhodiola. And the company's team building, injecting capital into private enterprises.
It is reported that Shandong Henglu Biotechnology was founded in March 2018. It integrates R&D, production and sales. It has a number of leading core patents in the field of biotechnology, such as human milk oligosaccharides, marine biological peptides, and high-purity rhodiola. Technology, and successfully realized the transformation of scientific research achievements and the whole process of safe and green production mode in the fields of special medical formula food, biological medicine, medical cosmetics and other fields.
Fang Xu, the founder and chief scientist of Shandong Henglu Biotechnology, a doctoral supervisor of Shandong University, and an expert of the State Key Laboratory of Microbial Technology, who attended the signing ceremony on the day, told reporters that the company's team has been committed to combining modern biotechnology with "medicine and food from the same source" Combined, it gives new life to traditional Chinese meals. At present, there are many projects such as human milk oligosaccharides, salidroside, and sea cucumber peptides. The important role of related products in the field of "specific health food" and the field of medical beauty is being continuously explored and applied.
As an investor, Liu Liyong, chairman of Huayao Capital, attaches great importance to the value of the investee. He said that the first is the value of the team. Shandong Henglu Biotechnology has international innovative technology. In the field of biosynthesis, the team led by Fang Xu has reached the forefront of the world. Huayao Capital is optimistic about the overall "combat capability" of the team. Secondly, it is the product market. For example, human milk oligosaccharides have been listed as breast milk products in Europe, and will become a trend in China. Henglu Biological’s existing technology is ahead of foreign countries, which indicates a huge prospect for the industry market in the future.
The reporter learned from an interview that Fang Xu led the team to synthesize the two most important human milk oligosaccharides by adopting the "biological enzyme method" and "biocatalytic" technology, using a new process with independent intellectual property rights, breaking through the patent layout and technology of international giants monopoly. Regarding the development potential of the project, Fang Xu revealed that this project will build China's first human milk oligosaccharide production line (with an annual output of 200 tons), creating economic benefits of over one billion yuan. The "human milk oligosaccharide" industry is in a blue ocean situation, and the high barrier characteristics of the "biological enzyme method" technology make the company more likely to become a unicorn enterprise in the field of formula milk powder and special medical food raw material preparation. The "human milk oligosaccharide" project will also solve the "stuck neck" problem and "breastfeeding" problem in the Chinese maternal and infant milk powder market, and effectively improve the health and healthy development of Chinese infants and young children.
The picture shows Shandong Henglu Biological Research and Development Laboratory. The picture shows Shandong Henglu Biological Research and Development Laboratory. Regarding the high-purity rhodiola project, Fang Xu said that the salidroside contained in rhodiola is the core component of the method of overcoming altitude sickness and repairing the body damaged by long-term living in high-altitude areas. It is also the famous Chinese patent medicine Lianhua One of the core ingredients of Qingwen. However, Rhodiola rosea, which grows naturally on the Qinghai-Tibet Plateau, is extremely scarce, and after being collected by the world for a long time, it is now on the verge of extinction. The content of salidroside in the rhodiola plant is only 3/1000 to 5/1000, and the extracted salidroside biological preparation is also extremely precious. After years of repeated experiments and a lot of scientific research, the scientific research team successfully found a biotechnology to obtain high-quality and high-purity salidroside through enzymatic catalysis.
Shandong Henglu Biology, which has a number of leading projects in the biological field, has been highly concerned and "sought after" by domestic and foreign capital. Industrial Development Fund" invested more than 50 million yuan in Shandong Henglu Biology. According to Liu Liyong, in October 2020, the "Shandong Provincial Science and Technology Innovation Kinetic Energy Venture Capital Fund" invested by Shandong Province, Qingdao New and Old Kinetic Energy Fund, and Qingdao Convergence Holding Group invested 20 million yuan in Henglu Biotechnology; Jinan Zhongcaijin Investment Group The "Jinan Zhongzhengjin Industry Development Fund" invested by the company invested 10 million yuan. With this signing, the Jinan Zhongzheng Financial Industry Development Fund invested an additional 24 million yuan.
Liu Liyong said frankly that Huayao Capital has long paid attention to the team's research and development capabilities and related technical achievements of Shandong Henglu Biology in recent years, and aimed at the nodes that require capital intervention to play a role. Following the investment last year, Huayao Capital once again made additional investment in Shandong Henglu with an interval of less than half a year. "Although it seems to be an early-stage project, Henglu Bio has great potential in the future, and hopes to help the company achieve a new leap forward through investment."